TY  - GEN
AU  - Ramos,Carlos A
AU  - Ballard,Brandon
AU  - Zhang,Huimin
AU  - Dakhova,Olga
AU  - Gee,Adrian P
AU  - Mei,Zhuyong
AU  - Bilgi,Mrinalini
AU  - Wu,Meng-Fen
AU  - Liu,Hao
AU  - Grilley,Bambi
AU  - Bollard,Catherine M
AU  - Chang,Bill H
AU  - Rooney,Cliona M
AU  - Brenner,Malcolm K
AU  - Heslop,Helen E
AU  - Dotti,Gianpietro
AU  - Savoldo,Barbara
TI  - Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
SN  - 1558-8238
PY  - 2017///1024
KW  - Adult
KW  - Antineoplastic Agents
KW  - chemistry
KW  - Brentuximab Vedotin
KW  - CD28 Antigens
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Hodgkin Disease
KW  - immunology
KW  - Humans
KW  - Immunoconjugates
KW  - administration & dosage
KW  - Immunophenotyping
KW  - Ki-1 Antigen
KW  - metabolism
KW  - Lymphoma, Large-Cell, Anaplastic
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Neoplasm Recurrence, Local
KW  - Receptors, Antigen, T-Cell
KW  - T-Lymphocytes
KW  - cytology
KW  - Transplantation Conditioning
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1172/JCI94306
ER  -